
Kura Oncology (KURA) Stock Forecast & Price Target
Kura Oncology (KURA) Analyst Ratings
Bulls say
Kura Oncology Inc. demonstrates a positive outlook due to its promising pipeline, particularly with KO-2806's ability to enhance the efficacy of cabozantinib in treating resistant solid tumors, signaling innovative advancements in cancer therapies. The early commercial success of KOMZIFTI indicates robust market potential and anticipated growth momentum that could extend into 2026. Additionally, the company's strong cash position provides the necessary resources and flexibility to effectively advance its clinical and commercial objectives, reinforcing confidence in its future performance.
Bears say
Kura Oncology faces significant risks that could adversely affect its stock performance, primarily stemming from the potential failure or delay in the approval of key drug candidates such as ziftomenib and tipifarnib. The company's product pipeline may encounter setbacks, including inconclusive clinical trial results or safety issues that could impede development and diminish market competitiveness against emerging therapies. Additionally, financial challenges related to securing sufficient funding further exacerbate the risk profile, complicating Kura’s ability to advance its projects through the necessary stages of drug development.
This aggregate rating is based on analysts' research of Kura Oncology and is not a guaranteed prediction by Public.com or investment advice.
Kura Oncology (KURA) Analyst Forecast & Price Prediction
Start investing in Kura Oncology (KURA)
Order type
Buy in
Order amount
Est. shares
0 shares